首页> 美国卫生研究院文献>Bioengineered >FAM136A immunoreactivity is associated with nodal involvement and survival in lung adenocarcinoma in a Chinese case series.
【2h】

FAM136A immunoreactivity is associated with nodal involvement and survival in lung adenocarcinoma in a Chinese case series.

机译:FAM136A免疫反应与中国案例系列中肺腺癌的节点受累和生存有关。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Lung cancer patients with lymph node metastasis usually had short overall survival and occurred distant metastases at the early stage. However, some of these people did have more prolonged survival. The underlying reason is still unclear. In this study, we found a novel molecule, family with sequence similarity 136, member A gene (FAM136A). First, we performed immunohistochemistry for FAM136A in 177 lung carcinoma tissues. Second, we carried out in vitro studies by using A549 and PC-9. We detected FAM136A immunoreactivity in 79 out of 177 (44.6%) lung carcinoma tissues, and the FAM136A status was significantly associated with tumor T stage, lymph node metastasis, and the Tumor-Node-Metastasis (TNM) staging system in these cases. Importantly, it was significantly associated with the overall survival of the patients with lymph node metastasis, especially FAM136A positive patients, who had worse outcomes. Subsequent in vitro experiments revealed that the proliferation activity and migration property decreased both A549 and PC-9 lung carcinoma cells transfected with siRNA-FAM136A, and apoptosis reduced. Meanwhile, the expression of CDK4 and CDK6 decreased. FAM136A status would be a potent, worse prognostic factor in lung cancer patients with lymph node metastasis. It would play a vital role in the proliferation, apoptosis, and migration properties of A549 and PC-9. In the future, We will focus on the uncovered signal mechanism between FAM136A and lung cancer.
机译:肺癌患者淋巴结转移通常在早期的整体存活中含有短暂的总存活,并且在早期发生转移。然而,其中一些人确实有更长时间的生存。潜在的原因尚不清楚。在这项研究中,我们发现一种新的分子,具有序列相似性的家族136,成员A基因(FAM136A)。首先,我们在177个肺癌组织中对FAM136A进行免疫组化。其次,我们通过使用A549和PC-9进行体外研究。我们检测到177个(44.6%)肺癌组织中79中的FAM136A免疫反应性,并且在这些情况下,FAM136A状态与肿瘤T阶段,淋巴结转移和肿瘤节点转移(TNM)分期系统显着相关。重要的是,它与淋巴结转移患者的整体存活率显着相关,特别是FAM136A阳性患者,他们具有更糟糕的结果。随后的体外实验表明,增殖活性和迁移性能降低了用SiRNA-FAM136A转染的A549和PC-9肺癌细胞,细胞凋亡降低。同时,CDK4和CDK6的表达降低。 FAM136A状态是淋巴结转移肺癌患者的有效性,更糟糕的预后因素。它将在A549和PC-9的增殖,细胞凋亡和迁移性质中发挥重要作用。未来,我们将专注于FAM136A和肺癌之间的未覆盖信号机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号